Boehringer Ingelheim announces acquisition of T3 Pharmaceuticals
Boehringer Ingelheim has announced the acquisition of Switzerland-based biotech company T3 Pharmaceuticals in a deal valued at up to CHF450m ($509m).
Simon Ittig News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Simon Ittig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Simon Ittig Today - Breaking & Trending Today
Boehringer Ingelheim expands immunooncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Boehringer Ingelheim today announced the acquisition of privatelyheld T3 Pharmaceuticals AG T3 Pharma a clinical stage Swiss biotech company for an amount of up to 450 million CHF.
Source: businesswireindia.com
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer ...
Source: pharmiweb.com
Six Swiss individuals that are making the world a better place
Researching cancer treatments, saving coral reefs or developing sustainable packaging: meet 6 Swiss working to make the world a better place.
Source: swissinfo.ch
Cell and gene therapies gain momentum in Basel
A growing number of companies specializing in the R&D of cell and gene therapies are choosing the Swiss city of Basel as their base.
Source: labiotech.eu